These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 31173759)

  • 1. Development of vaccines to treat opioid use disorders and reduce incidence of overdose.
    Pravetoni M; Comer SD
    Neuropharmacology; 2019 Nov; 158():107662. PubMed ID: 31173759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacious Vaccine against Heroin Contaminated with Fentanyl.
    Hwang CS; Smith LC; Natori Y; Ellis B; Zhou B; Janda KD
    ACS Chem Neurosci; 2018 Jun; 9(6):1269-1275. PubMed ID: 29558798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines as Immunotherapies for Substance Use Disorders.
    Kosten TR
    Am J Psychiatry; 2024 May; 181(5):362-371. PubMed ID: 38706331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapeutic strategies for treating opioid use disorder and overdose.
    Luba R; Martinez S; Jones J; Pravetoni M; Comer SD
    Expert Opin Investig Drugs; 2023 Jan; 32(1):77-87. PubMed ID: 36696567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose.
    Laudenbach M; Baruffaldi F; Robinson C; Carter P; Seelig D; Baehr C; Pravetoni M
    Sci Rep; 2018 Apr; 8(1):5508. PubMed ID: 29615715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymer-mediated delivery of vaccines to treat opioid use disorders and to reduce opioid-induced toxicity.
    Gradinati V; Baruffaldi F; Abbaraju S; Laudenbach M; Amin R; Gilger B; Velagaleti P; Pravetoni M
    Vaccine; 2020 Jun; 38(30):4704-4712. PubMed ID: 32439214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological mechanisms underlying the efficacy of antibodies generated by a vaccine to treat oxycodone use disorder.
    Raleigh MD; King SJ; Baruffaldi F; Saykao A; Hamid FA; Winston S; LeSage MG; Pentel PR; Pravetoni M
    Neuropharmacology; 2021 Sep; 195():108653. PubMed ID: 34126123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Efficacy and Characterization of Candidate Vaccines for Treatment of Opioid Use Disorders Using Clinically Viable Carrier Proteins.
    Baruffaldi F; Kelcher AH; Laudenbach M; Gradinati V; Limkar A; Roslawski M; Birnbaum A; Lees A; Hassler C; Runyon S; Pravetoni M
    Mol Pharm; 2018 Nov; 15(11):4947-4962. PubMed ID: 30240216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation and Characterization of Conjugate Vaccines to Reduce Opioid Use Disorders Suitable for Pharmaceutical Manufacturing and Clinical Evaluation.
    Baruffaldi F; Raleigh MD; King SJ; Roslawski MJ; Birnbaum AK; Hassler C; Carroll FI; Runyon SP; Winston S; Pentel PR; Pravetoni M
    Mol Pharm; 2019 Jun; 16(6):2364-2375. PubMed ID: 31018096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and circumstances of heroin and pharmaceutical opioid overdose deaths: Comparison across opioids.
    Roxburgh A; Hall WD; Gisev N; Degenhardt L
    Drug Alcohol Depend; 2019 Dec; 205():107533. PubMed ID: 31704378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accidental Overdose Deaths in Oklahoma, 2002-2017: Opioid and Methamphetamine Trends.
    Bonk R; Miller RJ; Lanter J; Niblo C; Kemp J; Shelton J
    J Anal Toxicol; 2020 Oct; 44(7):672-678. PubMed ID: 32542332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in heroin and pharmaceutical opioid overdose deaths in Australia.
    Roxburgh A; Hall WD; Dobbins T; Gisev N; Burns L; Pearson S; Degenhardt L
    Drug Alcohol Depend; 2017 Oct; 179():291-298. PubMed ID: 28826104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvements on a chemically contiguous hapten for a vaccine to address fentanyl-contaminated heroin.
    Park H; Lee JC; Eubanks LM; Ellis B; Zhou B; Janda KD
    Bioorg Med Chem; 2021 Jul; 41():116225. PubMed ID: 34034147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse.
    Raleigh MD; Peterson SJ; Laudenbach M; Baruffaldi F; Carroll FI; Comer SD; Navarro HA; Langston TL; Runyon SP; Winston S; Pravetoni M; Pentel PR
    PLoS One; 2017; 12(12):e0184876. PubMed ID: 29194445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acceptability of a Fentanyl Vaccine to Prevent Opioid Overdose and Need for Personalized Decision-Making.
    Weitzman ER; Kossowsky J; Blakemore LM; Cox R; Dowling DJ; Levy O; Needles EW; Levy S
    Clin Infect Dis; 2022 Aug; 75(Suppl 1):S98-S109. PubMed ID: 35579508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders.
    Robinson C; Baehr C; Schmiel SE; Accetturo C; Mueller DL; Pravetoni M
    Hum Vaccin Immunother; 2019; 15(4):909-917. PubMed ID: 30625019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lay knowledge and practices of methamphetamine use to manage opioid-related overdose risks.
    Daniulaityte R; Silverstein SM; Getz K; Juhascik M; McElhinny M; Dudley S
    Int J Drug Policy; 2022 Jan; 99():103463. PubMed ID: 34619443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unique Pharmacology, Brain Dysfunction, and Therapeutic Advancements for Fentanyl Misuse and Abuse.
    Han Y; Cao L; Yuan K; Shi J; Yan W; Lu L
    Neurosci Bull; 2022 Nov; 38(11):1365-1382. PubMed ID: 35570233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining opioid-involved overdose mortality trends prior to fentanyl: New York City, 2000-2015.
    Tuazon E; Kunins HV; Allen B; Paone D
    Drug Alcohol Depend; 2019 Dec; 205():107614. PubMed ID: 31689642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Housing conditions and microbial environment do not affect the efficacy of vaccines for treatment of opioid use disorders in mice and rats.
    Crouse B; Zhang L; Robinson C; Ban Y; Vigliaturo JR; Roy S; Pravetoni M
    Hum Vaccin Immunother; 2021 Nov; 17(11):4383-4392. PubMed ID: 34411500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.